Rebuilt Version of ALSGene Database Ready for Prime Time
A new interface allows researchers to mix and match data from genome-wide association studies in search of genes involved in sporadic amyotrophic lateral sclerosis.
81 RESULTS
Sort By:
A new interface allows researchers to mix and match data from genome-wide association studies in search of genes involved in sporadic amyotrophic lateral sclerosis.
A novel mutation frays mitochondrial DNA and impedes ATP synthesis in people with an ALS-FTD-like syndrome.
Several thousand people have used preimplantation genetic diagnosis to avoid passing on pathogenic mutations to their babies, but many families with a history of Alzheimer’s or related diseases remain unaware of this option.
Families considering PGD to avoid passing on disease genes face obstacles such as high cost and invasive procedures.
Researchers retract two papers that claimed a quick dunk in acid turns mature mouse lymphocytes into pluripotent cells.
An award-winning film follows a social worker set on bringing music to people with dementia, and documents their unforgettable moments of awakening.
Antipsychotic medications repurposed to accelerate autophagy might prevent cellular toxicity associated with mutant TDP-43.
In a large retrospective study, people with the highest plasma levels of an inflammatory protein experienced the greatest decline in reasoning abilities over the next 10 years.
In fruit flies that model ALS, presynaptic vesicles gather in unusually large clumps, amplifying signaling at the neuromuscular junction. Does this promote disease?
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
The enzyme PARC acts as a survival factor in damaged neurons and cancer cells by targeting a pro-apoptotic protein for destruction.
Novartis to Partner with Banner Health on ApoE4 Prevention Trial Crenezumab Disappoints in Phase 2, Researchers Remain Hopeful Alzheimer’s Disease: In the Eye of the Patient? References and Thresholds—Amyloid Imaging Protocols Debated at AAIC Anti-Amyloid
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Could tweaking methodologies improve amyloid diagnosis and tracking?
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.